1979 (v1)
Publication
No description
Uploaded on: March 31, 2023
B
Last name: BREMA F
No description
No description
No description
Background. To determine whether a dose-dense regimen improves outcome in early breast cancer patients, we compared outcomes with the same fluorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapeutic regimen administered every 3 weeks (FEC21) or administered every 2 weeks (FEC14 including support with filgrastim, a granulocyte...